Clinical Trial

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

Study acronym: Rebalance-HF
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this clinical study is to evaluate the safety and early effectiveness of a catheter-based procedure that treats a nerve called the right greater splanchnic nerve. The study includes people who have heart failure with preserved ejection fraction (HFpEF). The goal is to learn whether this procedure, performed using the Satera Ablation System, may help improve symptoms and to better understand which patients may benefit most from this treatment in the future.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-10-13; most recent amendment 2026-03-10.
Status change: Not Yet Recruiting → Recruiting 2021-09-15
Trial Details
NCT Number NCT04592445
Lead Sponsor Axon Therapies, Inc.
Collaborators: NAMSA, Cardiovascular Research Foundation, New York, Northwestern University
Conditions Heart Failure With Preserved Ejection Fraction (HFpEF
Enrollment 150 participants
Start Date 2020-12-18
Primary Completion 2028-01-10 (estimated)
Study Completion 2029-08-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-13